Zacks Investment Research on MSN
Can Merck's new drugs & pipeline ease Keytruda LOE concerns?
Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2028.
Merck & Co., Inc. (NYSE:MRK) is one of Goldman Sachs top healthcare stocks. On March 3 at the TD Cowen 46th Annual Health Care Conference, Merck & Co., Inc. (NYSE:MRK) unveiled strategic initiatives ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results